Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2020

View Archived Issues

Helping hand for protein sorting prevents AD

Mutant TP53 affects fat metabolism

Skin-deep defense may be good enough for arboviruses

New phase I trial studies monoclonal antibody CIS-43LS against malaria

Topline data from phase III VELOS-2 study of HL-036

Blueberry Therapeutics receives IND clearance from the FDA for BB-2603

TRuE-AD2 pivotal phase III study of ruxolitinib cream meets primary endpoint

First patient dosed in phase I study of SY-5609

FDA approves first human trials of Myeliviz for PET imaging in MS

V-4020, a novel VEEV vaccine with increased safety and stability

cis-Regulatory elements of the FOXA1 plexus as therapeutic targets in prostate cancer

Results from phase I/II COMPOSER study of crovalimab

Janssen presents phase II results for daratumumab in relapsed AL amyloidosis

Melanocortin MC2 receptor antagonists disclosed by Crinetics Pharmaceuticals

Saint Louis University, Indalo Therapeutics patent integrin alphavbeta1/alpha5beta1 antagonists

Idorsia Pharmaceuticals discovers OX1/OX2 receptor antagonists

Servier, Vernalis identify new ubiquitin carboxyl-terminal hydrolase 7 inhibitors

Nuclear receptor ROR-gamma antagonists discovered at Sunshine Lake Pharma

Trovagene presents update on phase Ib/II trial of onvansertib

Feisty old folks: Sprightly genomes bring insights into healthy aging, early-onset illness

Enrollment open in first-in-human study of CC-97540 in NHL

Phase II study of AKCEA-ANGPTL3-LRx meets primary endpoint of significant triglyceride lowering

Clover begins development of recombinant subunit vaccine for 2019-nCoV

CytoDyn explores use of leronlimab for novel coronavirus

Avacta demonstrates proof of concept for TMAC platform in animal model of cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...